Treatment of recurrent malignant gliomas with fotemustine monotherapy: impact of dose and correlation with MGMT promoter methylation

BACKGROUND: In recurrent malignant gliomas (MGs), a high rate of haematological toxicity is observed with the use of fotemustine at the conventional schedule (100 mg/m(2 )weekly for 3 consecutive weeks followed by triweekly administration after a 5-week rest period). Also, the impact of O6-methylgua...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Fabi, Alessandra, Metro, Giulio, Russillo, Michelangelo, Vidiri, Antonello, Carapella, Carmine Maria, Maschio, Marta, Cognetti, Francesco, Jandolo, Bruno, Mirri, Maria Alessandra, Sperduti, Isabella, Telera, Stefano, Carosi, Mariantonia, Pace, Andrea
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2009
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2667532/
https://ncbi.nlm.nih.gov/pubmed/19335893
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-9-101
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars